{"id":"W4281670534","doi":"10.1200/jco.2022.40.16_suppl.tps5103","title":"DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Ottawa Hospital; McGill University; Queen Elizabeth II Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Clinical endpoint; Placebo; Internal medicine; Docetaxel; Randomization; Oncology; Randomized controlled trial; Antiandrogen; Tolerability; Prostatectomy; Urology; Cancer; Adverse effect; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002230891,0.001952427,0.002665527,0.0007791077,0.0005263122,0.001104429,0.001552621,0.002080013,0.008948656],"category_scores_gemma":[0.001522422,0.0008165213,0.001751222,0.0005523068,0.001600034,0.001019869,0.0005466351,0.003697579,0.001273122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000783929,"about_ca_system_score_gemma":0.00203866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001082123,"about_ca_topic_score_gemma":0.002390686,"domain_scores_codex":[0.999321,0.0003898294,0.0000327226,0.0001043752,0.0000528998,0.00009917871],"domain_scores_gemma":[0.999068,0.000221214,0.0001965637,0.00006755043,0.00005694612,0.0003898961],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9697529,0.01122613,0.0002905766,0.0006623685,0.0005910159,0.00002635105,0.00003600916,0.0002780335,0.002881118,0.0001475872,0.001069018,0.013039],"study_design_scores_gemma":[0.931839,0.0664165,0.0005155497,0.00001889927,0.0001669546,0.00001937412,0.000009143284,0.0001760035,0.0003508917,0.00006311815,0.0004141423,0.00001034543],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.97686,0.00595917,0.0007962355,0.0006779994,0.0006848025,0.009684757,0.001834697,0.0003713421,0.003130858],"genre_scores_gemma":[0.9730238,0.003552433,0.002809336,0.001429428,0.0004908266,0.01223669,0.001863412,0.00004646666,0.004547543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008948656,"threshold_uncertainty_score":0.02993625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1213833281091303,"score_gpt":0.4691233173216555,"score_spread":0.3477399892125252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}